Amerigen has reached an agreement with UPM to commercially manufacture two ANDA products



US CONTACT: (732) 993-9821
CHINA CONTACT: +86-512-6745-1085 ext 101

April 2, 2014. Amerigen Pharmaceuticals, Inc. has reached an agreement with UPM, a division of Gregory Pharmaceutical Holdings, Inc., for UPM to commercially manufacture two ANDA products for a 10 year supply term.  In addition, the agreement allows for UPM to develop and potentially commercially supply several additional ANDA products for Amerigen over the next few years.  UPM acquired the 475,000 square foot Pfizer manufacturing facility in Bristol, Tennessee in July of 2013 and, eventually, all of these products will be made at this new facility.

Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, Inc., said, “UPM has been working with Amerigen for the past three years providing development services for their significant pipeline of ANDA products.  We have a strong working relationship with their company and are impressed with their technical team and their business development approach.  We believe this agreement cements our partnership with Amerigen.  Also, it is another example of UPM’s transition from a company that formerly focused on only early stage development, but now, provides a full range of solid dose commercial services for our clients.”

Jonathan Embleton, Chief Business Officer of Amerigen, said, “Amerigen looks forward to a long relationship with UPM.  We are excited about our upcoming product portfolio and the role UPM will play in providing products to market.”


Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has products on the market currently in both the US and China plus an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese CFDA. Amerigen's focus is orally delivered products that are potential first generics, challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.